AbbVie struck a licensing and development deal with Zelgen Biopharmaceuticals to advance a clinical-stage DLL3-targeted T‑cell engager in China. The agreement gives AbbVie access to Zelgen’s T-cell engager asset and local development rights, accelerating the company’s immuno-oncology footprint in Greater China. The deal follows AbbVie’s earlier 2025 investments in T‑cell engager programs and reflects continued pharma interest in DLL3 as a target for small‑cell and neuroendocrine tumors. The collaboration covers clinical development and commercialization in China, with financial terms not disclosed publicly. For industry readers: a T‑cell engager is a bispecific molecule that recruits T cells to tumor cells by binding CD3 on T cells and a tumor antigen, enabling targeted cytotoxicity without autologous cell manufacture. Why it matters: the deal signals Big Pharma’s ongoing strategy to partner with China-based developers to speed regional trials and regulatory filings for next‑generation immunotherapies.